Sentence examples similar to supporting cost effectiveness from inspiring English sources

There is limited evidence to support cost effectiveness of population screening in rheumatoid arthritis and case finding strategies have been proposed as a means to increase cost effectiveness of diagnostic screening for osteoporosis.

There is insufficient evidence supporting cost-effectiveness or outcomes for recommending the utilization of gadoxetic acid-enhanced MRI for HCC screening at this time.

The collection of preference-based health outcomes data (or utility values) is required to support cost-effectiveness analyses.

Studies support cost-effectiveness of HHD when compared to ICHD.

Such reasoning has been used to support cost-effectiveness analyses of the TST and QFT for diagnosis of LTBI [ 36].

We performed a Markov model supported cost-effectiveness analysis to compare costs and QALYs of nab-paclitaxel and conventional paclitaxel in MBC patients.

This is of less relevance when considering the use of these equations to support cost-effectiveness analyses because it is the incremental difference in event rates (typically driven by risk factors reported in randomized clinical trials) that is important.

Two studies support cost-effectiveness in ER+ populations, but in ER− patients and in a mixed (ER+, ER−) population, the clinical outcomes were poorer following MammaPrint testing than with usual care.

Whilst there is some evidence to support cost-effectiveness of screening and treating post menopausal women with rheumatoid arthritis who are starting corticosteroid treatment [ 13], the cost effectiveness of screening an unselected post-menopausal rheumatoid arthritis population has not been reported.

In contrast, there is level 3 evidence from a matched case control study, which also did not include informal care costs, supporting the cost effectiveness of donepezil (Hill et al. 2002).

Evidence supporting the cost effectiveness of universal screening is mixed (Yonkers et al. 2009; Mitchell and Coyne 2009), with some studies showing that lack of access to treatment undermines the cost effectiveness of universal screening (Paulden et al. 2009), as does offering treatment to women who do not need it or to those who do not want it (Dowswell et al. 2010).